Evidence map›Paper›PMID 22692002›Full record

ReviewAutophagy2012

Emerging role of autophagy in kidney function, diseases and aging.

Tobias B Huber, Charles L Edelstein, Björn Hartleben, Ken Inoki, Man Jiang, Daisuke Koya, Shinji Kume, Wilfred Lieberthal, Nicolas Pallet, Alejandro Quiroga and 4 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Autophagy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 1 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 1 synthesis or guideline pooled it, 249 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. A novelRenal failure · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 5 countries.

Tobias B HuberRenal Division, University Hospital Freiburg; Freiburg, Germany. tobias.huber@uniklinik-freiburg.de
Charles L Edelstein
Björn Hartleben
Ken Inoki
Man Jiang
Daisuke Koya
Shinji Kume
Wilfred Lieberthal
Nicolas Pallet
Alejandro Quiroga
Kameswaran Ravichandran
Katalin Susztak
Sei Yoshida
Zheng Dong
University Medical Center Freiburg · DEUniversity of Colorado Denver · USAlbert Einstein College of Medicine · USAnn Arbor Center for Independent Living · USAugusta University · USCharlie Norwood VA Medical Center · USKanazawa Medical University · JPShiga University of Medical Science · JPStony Brook University Hospital · USThe Bronx Defenders · USUniversité Paris Cité · FRUniversity of Michigan–Ann Arbor · US

Funding

DNA methylation in kidney repair after ischemic AKIR01DK058831 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DONG, ZHENG · 2001 to 2025
$7.5M
Epigenetics of Chronic Kidney DiseaseR01DK087635 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATALIN SUSZTAK · 2009 to 2026
$7.0M
Kidney Injury by Cisplatin and Renoprotective Strategies.R01DK087843 · NIDDK · AUGUSTA UNIVERSITY · PI DONG, ZHENG · 2010 to 2025
$5.8M
Role of TSC-mTORC1 pathway for podocyte injury in diabetic nephropathyR01DK083491 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI INOKI, KEN · 2009 to 2017
$3.0M
ROLE OF CASPASES IN ISCHEMIC ACUTE RENAL FAILURER01DK056851 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI EDELSTEIN, CHARLES LOUIS · 2001 to 2010
$2.5M
Lysosomal cholesterol-dependent anabolic regulationR01DK124709 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI INOKI, KEN · 2022 to 2025
$2.1M
Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)R01DK074835 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI EDELSTEIN, CHARLES LOUIS · 2007 to 2011
$1.8M
NIDDK NIH HHS DK058831NIDDK NIH HHS DK074835NIDDK NIH HHS DK083491NIDDK NIH HHS DK087843NIDDK NIH HHS R01 DK056851NIDDK NIH HHS R01DK056851NIDDK NIH HHS R01 DK058831NIDDK NIH HHS R01 DK074835NIDDK NIH HHS R01 DK083491NIDDK NIH HHS R01 DK087635NIDDK NIH HHS R01 DK087843NIDDK NIH HHS R01 DK124709
6 · The paper itself

Abstract

Autophagy is a highly conserved process that degrades cellular long-lived proteins and organelles. Accumulating evidence indicates that autophagy plays a critical role in kidney maintenance, diseases and aging. Ischemic, toxic, immunological, and oxidative insults can cause an induction of autophagy in renal epithelial cells modifying the course of various kidney diseases. This review summarizes recent insights on the role of autophagy in kidney physiology and diseases alluding to possible novel intervention strategies for treating specific kidney disorders by modifying autophagy.

Indexed as

AutophagyAgingHealthHumansKidneyKidney DiseasesModels, Biologicalacute kidney injuryagingautophagyglomeruluskidneykidney transplantationmTORpodocytepolycystic kidney disease

Identifiers

PMID22692002
PMCPMC3429540
OpenAlexW2012371191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.